Showing 3871-3880 of 9336 results for "".
- Aesthetic Sequelae of GLP-1 Receptor Agonists Highlighted in Clinical Reviewhttps://practicaldermatology.com/news/aesthetic-sequelae-of-glp-1-receptor-agonists-highlighted-in-clinical-review/2485615/Dermatologists are increasingly encountering aesthetic complications associated with GLP-1 receptor agonist (RA)–induced weight loss, according to a clinical review presented at the South Beach Symposium. The poster, b
- Prolactin Receptor Blockade May Promote Hair Growth via Follicular Stem Cell Activationhttps://practicaldermatology.com/news/prolactin-receptor-blockade-may-promote-hair-growth-via-follicular-stem-cell-activation/2485612/Blocking prolactin receptor (PRLR) signaling with the investigational antibody ABS-201 promoted hair follicle growth and stem cell activation in human male scalp skin models, according to preclinical data from Jérémy Chéret, PhD, MSc, at the South Beach Symposium
- Delgocitinib Improves Patient-Reported Outcomes Across Chronic Hand Eczema Subtypeshttps://practicaldermatology.com/news/delgocitinib-improves-patient-reported-outcomes-across-chronic-hand-eczema-subtypes/2485611/Patient-reported outcome (PRO) data from the phase 3 DELTA 1 and DELTA 2 trials suggest that topical delgocitinib cream provides clinically meaningful symptom relief across major subtypes of chronic hand eczema (CHE), according to a poster from Robert Bissonnette,
- FDA Accepts Galderma’s RelabotulinumtoxinA BLA Resubmissionhttps://practicaldermatology.com/news/fda-accepts-galdermas-relabotulinumtoxina-bla-resubmission/2485601/Galderma announced that the US Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Application (BLA) for relabotulinumtoxinA (Relfydess™) for the temporary improvement of moderate-to-severe glabellar lines and lateral canthal lines in a
- Fever and Abdominal Purpura Linked to IgAV Recurrence in Adultshttps://practicaldermatology.com/news/fever-and-abdominal-purpura-linked-to-igav-recurrence-in-adults/2485592/Systemic corticosteroids and post-bacterial etiology may protect against recurrence or relapse in adult immunoglobulin A vasculitis (IgAV), a new study suggests. Investigators for the retrospective cohort study
- Analysis: ChatGPT and DeepSeek Largely Align With Psoriasis Treatment Guidelineshttps://practicaldermatology.com/news/analysis-chatgpt-and-deepseek-largely-align-with-psoriasis-treatment-guidelines/2485578/Large language models (LLMs) ChatGPT and DeepSeek generally adhere to established psoriasis treatment guidelines, but some performance gaps remain. Investigators publishing in the Journal of Drugs in Dermatology exp
- Nutrafol Launches Men 50+ Formula Targeting Age-Related Hair Thinninghttps://practicaldermatology.com/news/nutrafol-launches-men-50-formula-targeting-age-related-hair-thinning/2485568/Nutrafol announced an expansion of its men’s portfolio with the launch of Nutrafol Men 50+, a product designed specifically for men aged 50 years and older with thinning hair. According to the company, men entering their 50s ex
- AbbVie Files FDA, EMA Applications for Upadacitinib in Non-Segmental Vitiligohttps://practicaldermatology.com/news/abbvie-files-fda-ema-applications-for-upadacitinib-in-non-segmental-vitiligo/2485564/AbbVie has submitted regulatory applications to the US Food and Drug Administration and European Medicines Agency seeking approval of upadacitinib (RINVOQ) for the treatment of adults and adolescents with non-segmental vitiligo (NSV), according to a
- Deuruxolitinib Produces Progressive Hair Regrowth in Severe Alopecia Areatahttps://practicaldermatology.com/news/deuruxolitinib-produces-progressive-hair-regrowth-in-severe-alopecia-areata/2485553/Deuruxolitinib produced progressive and clinically meaningful scalp hair regrowth in patients with severe alopecia areata, according to “Deuruxolitinib Improves Scalp Hair Regrowth Over Time in Patients With Severe Alopecia Areata,” a poster by Natasha A. Mesinkovska, MD, PhD, et al presented as
- 23-Gene Expression Profiling Accurately Classifies Pediatric Melanocytic Lesionshttps://practicaldermatology.com/news/23-gene-expression-profiling-accurately-classifies-pediatric-melanocytic-lesions/2485549/A 23-gene expression profiling assay accurately distinguished benign nevi from melanoma in pediatric patients, according to “23-GEP Accurately Distinguishes Between Melanocytic Nevi and Melanoma in Pediatric Melanocytic Neoplasms,” a poster by Drazen Jukic, MD, et al presented as part of the “Bes